|1.||Yamamoto, Kouji: 6 articles (01/2006 - 07/2002)|
|2.||Nakano, Takeshi: 5 articles (10/2005 - 07/2002)|
|3.||Shimizu, Atsuya: 5 articles (10/2005 - 07/2002)|
|4.||Shiraki, Katsuya: 5 articles (10/2005 - 07/2002)|
|5.||Hashimoto, Akira: 5 articles (10/2005 - 07/2002)|
|6.||Moriyasu, Fuminori: 4 articles (03/2012 - 05/2005)|
|7.||Kondo, Takashi: 4 articles (06/2008 - 05/2002)|
|8.||Nakanishi, Shigeo: 4 articles (10/2005 - 02/2003)|
|9.||Fuke, Hiroyuki: 4 articles (10/2005 - 02/2003)|
|10.||Kudo, Masatoshi: 3 articles (07/2010 - 07/2003)|
04/01/1998 - "These findings were characteristic in various hepatic tumors, and color Doppler echography enhanced by Levovist was very useful to distinguish hepatic tumors."
05/01/1994 - "Levovist improved the depiction of tumor vessels in all cases and helped detect new vascular signals which had been missed on baseline images. "
05/01/2005 - "The aims of the present study were: to assess standard ultrasound and color-Doppler patterns for the study and characterization of salivary gland tumors; to define the improvement in the color-Doppler ultrasound image after injection of a signal amplifier (Levovist); to compare morphological and vascular aspects of the neoplasm with data obtained during postoperative histopathological analysis. "
05/01/2006 - "The aim of this study was to define the usefulness of contrasting agent Levovist in differential diagnostics of adrenal tumors and its influence on sensitivity and specificity of ultrasound examination and to establish patients qualification criteria for surgical procedures. "
05/01/2000 - "Objective of the present study was the comparison of various administration forms of the ultrasound contrast medium Levovist with regard to duration and intensity of contrast enhancement in patients with tumors of the liver or pancreas. "
|2.||Hepatocellular Carcinoma (Hepatoma)
05/01/1994 - "To assess the efficacy of a new US contrast agent [SH U 508 A (Levovist), Schering] in evaluating hepatocellular carcinoma (HCC) vascularization, 38 patients with 43 lesions were submitted to color Doppler US before and after i.v. contrast medium administration. "
11/01/2003 - "The objective of this study was to compare Levovist power Doppler ultrasound (Levovist US) with contrast-enhanced spiral computed tomography (spiral CT), in the evaluation of the efficacy of percutaneous local ablation procedures, in patients with hepatocellular carcinoma (HCC). "
05/01/1994 - "Efficacy of SH U 508 A (Levovist) in color Doppler ultrasonography of hepatocellular carcinoma vascularization."
06/01/2003 - "The purpose of the study was to assess contrast enhancement patterns of hepatic tumours during the vascular phase using contrast-enhanced ultrasound and Levovist to differentiate hepatocellular carcinoma from other hepatic tumours. "
07/01/2007 - "Contrast-enhanced ultrasound with Levovist facilitates the application of percutaneous ultrasound-guided treatment by improving localization of ultrasonically invisible hypervascular hepatocellular carcinomas in the liver."
|3.||Neoplasm Metastasis (Metastasis)
05/01/2001 - "Contrast-enhanced phase-inversion sonography in the liver-specific phase of contrast enhancement using Levovist provides a marked improvement in the detection of hepatic metastases relative to unenhanced conventional sonography, without loss of specificity. "
05/01/2002 - "Improved detection of liver metastases with phase inversion ultrasound during the late phase of levovist."
01/01/1999 - "Improved detection of liver metastases with phase inversion imaging during the liver-specific phase of the ultrasound contrast agent levovist."
03/01/2003 - "The aim of this study was to evaluate capabilities of pulse inversion harmonic imaging (PIHI) with Levovist in detection of liver metastases compared with conventional ultrasound (US) and helical CT (HCT). "
05/01/2001 - "The purpose of our study was to assess whether phase-inversion sonography during the late, liver-specific phase of contrast enhancement using Levovist improves the detection of hepatic metastases relative to unenhanced conventional B-mode sonography. "
|4.||Mitral Valve Insufficiency (Mitral Regurgitation)
08/01/1993 - "Flow detection improved, as shown by the increased jet area of mitral regurgitation (> or = 170%), after 3 g of SHU 508 A (3 +/- 3 vs. 12 +/- 8 cm2, p < 0.001) and by a > or = 200% increase in normal anterograde flow area (p < 0.001) in both the mitral regurgitation group and the control group. "
08/01/1993 - "Control subjects (n = 10) and patients with suspected mitral regurgitation (n = 23) were studied by color Doppler flow imaging before and after 3-g intravenous doses of SHU 508 A. "
07/01/2001 - "SHU 508 A is especially useful in improving the severity grading of aortic stenosis and aortic regurgitation, while grading of mitral stenosis and mitral regurgitation is less improved."
04/01/2000 - "To investigate if the use of a contrast agent (Levovist) improves the specificity of US in the diagnosis of prostate carcinoma, having the results of prostate biopsy as the gold standard. "
01/01/2005 - "We studied 50 patients affected by locally advanced breast carcinoma (T3a e b-T4), using CDU before and after injection of Levovist, prior to and after neoadjuvant chemotherapeutic treatment. "
01/01/2003 - "In the 16 patients with prostate carcinoma, the sensitivity of CDU after Levovist was 92.3, 66% for both DRE and TRUS, and 80% for DRE plus TRUS. "
01/01/1994 - "The vascularity of adnexal masses with a suspicion of primary carcinoma in 3 and benign lesions in 27 cases was investigated before and after injection of 300 mg/ml of Levovist. "
01/01/2005 - "The aim of our study was to assess the color-Doppler ultrasound (CDU) pattern in the analysis of neoadjuvant preoperative treatment of patients with locally advanced breast carcinoma, improvement after injection of contrast medium (Levovist) and possible correlations between morphological and vascular aspects of the neoplasm and postoperative histopathological findings. "
|3.||glucuronyl glucosamine glycan sulfate (Vessel)
|5.||Ethanol (Ethyl Alcohol)
|6.||3-chloro-4,4-dimethyl-2-oxazolidinone (agent I)
|7.||FS 069 (Optison)
|8.||contrast agent BR1
|9.||SHU 508 (Levovist)
|10.||Palmitic Acid (Hexadecanoic Acid)
|5.||Infusion Pumps (Infusion Pump)